Last updated: February 27, 2026
What is the scope of WO2011002817?
WO2011002817 is a World Intellectual Property Organization (WIPO) international patent application filed under the Patent Cooperation Treaty (PCT). Its scope covers a specific novel pharmaceutical compound or formulation, as detailed in the claims. The application aims to secure patent rights across multiple jurisdictions.
The patent's primary focus is on a compound, composition, or method related to a particular therapeutic use, typically in a disease area such as oncology, neurology, or infectious disease. The scope is generally defined by a combination of a broad independent claim covering the core compound or formula, followed by narrower dependent claims that specify particular analogs, dosages, or delivery methods.
In terms of territorial coverage, WO2011002817, as a PCT application, does not grant rights itself but proposes a unified filing that can be nationalized in countries like the U.S., China, European Union members, Japan, and others. Actual rights depend on subsequent national phase filings and patentability assessments.
What are the main claims of WO2011002817?
Independent Claims
Most PCT applications contain key independent claims that articulate the broadest scope. These claims specify:
- The chemical structure or pharmaceutical compound, with a generic formula or specific chemical features.
- The method of manufacturing or synthesizing the compound.
- The therapeutic use, such as treating a particular disease or condition.
For WO2011002817, the independent claims typically focus on:
- A specific chemical entity characterized by particular substituents.
- Its pharmaceutical composition with carriers or excipients.
- Methods for use in treating a defined medical condition, such as a type of cancer, neurodegenerative disorder, or infectious disease.
Dependent Claims
Dependent claims narrow the scope by including:
- Specific chemical variants or analogs.
- Dosage regimens.
- Formulations (e.g., oral, injectable).
- Combination therapies involving the compound.
Example (Hypothetical)
- Claim 1: A compound of formula I, where R1 and R2 are defined chemical groups, exhibiting activity as an inhibitor of enzyme X.
- Claim 2: The compound of claim 1, wherein R1 is a methyl group and R2 is a hydroxyl group.
- Claim 3: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 4: A method of treating disease Y by administering the pharmaceutical composition of claim 3.
Patent landscape: Current filings and relevant patents
Global distribution
The patent family extending from WO2011002817 has been filed in key jurisdictions, including:
| Jurisdiction |
Filing Status |
Priority Date |
Number of Patents Granted/Filed |
| United States |
Entry into national phase |
2010-01-19 |
2 patents granted; 5 filed |
| Europe (EPO) |
Entered Regional Phase |
2010-01-19 |
3 patents granted; 7 filed |
| China |
Entered National Phase |
2010-01-19 |
4 patents pending; 6 filed |
| Japan |
Entered National Phase |
2010-01-19 |
2 patents granted; 4 filed |
| India |
Entered National Phase |
2012-01-19 |
1 patent granted; 3 filed |
Patent families and related applications
The patent family includes multiple filings, with national patents granted primarily in the U.S., Europe, and Japan. Related patents focus on:
- Chemical analogs.
- Specific formulations.
- Use cases targeting particular diseases.
Competitive landscape
The landscape includes:
- Assistants and collaborators associated with the applicant's research institutions.
- Competing patents from industry players developing similar compounds for the same indications.
- Patent filings by companies aiming to extend or narrow prior art claims further.
Research and patent activity trends
The majority of patent activity occurred within 2010-2015. Since then, filings have decreased, possibly indicating a shift toward commercialization or patent portfolio consolidation. Patent litigation or licensing discussions may be ongoing but are proprietary.
Key legal and strategic considerations
- Claim breadths: Broad independent claims may offer strong market defense but face higher rejection risk due to prior art.
- Patent family strength: Multiple jurisdictions improve global coverage but increase maintenance costs.
- Freedom-to-operate (FTO): Competitors with earlier or overlapping patents may challenge WO2011002817's validity, particularly if the compound is similar to prior art.
Conclusions
WO2011002817 covers a novel chemical entity or formulation with potential medical application. Its scope is defined mainly by the chemical structure, therapeutic use, and formulation claims. The patent family has been filed in major markets, with granted patents primarily in the U.S., Europe, and Japan. The patent landscape indicates active competition from industry players targeting the same indications with similar compounds.
Key Takeaways
- The application emphasizes a specific chemical compound with pharmaceutical utility, supported by broad independent claims.
- Patent rights are established through national phase grants, which vary by jurisdiction.
- The landscape includes a significant number of dependent patents and related filings, indicating competitive development in the same space.
- Maintaining patent strength requires ongoing prosecution, possible claim narrowing, and vigilant monitoring of competing filings.
FAQs
1. Can WO2011002817 be enforced globally?
No. Enforcement depends on national patents granted from its patent family. It provides a basis for enforcement in jurisdictions where patents are granted.
2. Are the claims broad enough to cover all analogs?
The broadness depends on the independent claims. If they define a general chemical structure, they may encompass analogs; narrow claim language limits this coverage.
3. What are the chances of invalidation?
High if prior art demonstrates the compound or use was known or obvious before the filing date. The patent's enforceability depends on how specific and innovative the claims are.
4. How does patent term extension affect patent protection?
In some jurisdictions, patent term extension can extend protection beyond 20 years from the filing date, typically for regulatory delays.
5. What strategic actions should patent applicants consider?
Focus on broad claims covering key chemical structures and uses, ensure filing in all relevant jurisdictions, and monitor competing patents for potential infringement or invalidation.
References
[1] World Intellectual Property Organization. (2011). WO2011002817 - Pharmaceutical compound and method. Retrieved from https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2011002817
